Device Trial Radar · NCT04280029
SELUTION SLR™ 014 In-stent Restenosis
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
418
Actual
Start
Jul 6, 2020
Primary completion
Aug 15, 2025
Study completion Aug 2029
Sponsor
- Lead sponsor
- M.A. Med Alliance S.A.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd; Cordis US Corp.
- First posted
- Feb 21, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, multi-center, randomized, single blind, controlled, noninferiority clinical trial. Subjects with previous bare-metal stent (BMS) or Drug-Eluting Stent (DES) and qualifying evidence for In-stent Restenosis (ISR) will be screened per the protocol inclusion and exclusion criteria. Eligible subjects will be randomized 1:1 to treatment with either the SELUTION SLR 014 DEB or Standard of Care (SOC) to include contemporary DES (zotarolimus-eluting stents \[ZES\] and everolimus-eluting stents \[EES\] only) or Balloon Angioplasty (BA). A maximum of 20% of patients randomized to SOC will be treated with BA. The primary endpoint will be Target Lesion Failure (TLF) at 12-months in the SOC group vs. the SELUTION SLR 014 DEB in all patients.
Conditions
- Coronary Restenosis
Interventions
SELUTION SLR 014 DEBDevice
The SELUTION Sustained Limus Release (SLR)™ 014 drug-eluting balloon (DEB) catheter is a combination product consisting of a standard percutaneous transluminal angioplasty (PTA) balloon catheter coated with a drug (Sirolimus).
Standard of CareDevice
POBA or FDA-approved commercially available -limus eluting DES
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Target Lesion Failure (TLF)Time frame: 12 months post-index procedure
Locations
48 sites in 7 countries. Site status is shown where the registry gives one.
Loma Linda University
Loma Linda, California
Cedars-Sinai Medical Center
Los Angeles, California
Harbor-UCLA Medical Center
Torrance, California
45 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.